ASX - By Stock
|
RAC |
Re:
Ann: RC220 Meets Quality Specifications
|
|
SocialEddy
|
101 |
21K |
18 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
101
|
21K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 Meets Quality Specifications
|
|
SocialEddy
|
101 |
21K |
4 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
101
|
21K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 Meets Quality Specifications
|
|
SocialEddy
|
101 |
21K |
4 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
101
|
21K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: RC220 Meets Quality Specifications
|
|
SocialEddy
|
101 |
21K |
41 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
101
|
21K
|
41
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
SocialEddy
|
11K |
3.8M |
7 |
08/11/23 |
08/11/23 |
General
|
11K
|
3.8M
|
7
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
SocialEddy
|
21K |
7.3M |
1 |
07/11/23 |
07/11/23 |
ASX - By Stock
|
21K
|
7.3M
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Impressive Bisantrene Phase 2 AML Clinical Results
|
|
SocialEddy
|
231 |
66K |
9 |
07/11/23 |
07/11/23 |
ASX - By Stock
|
231
|
66K
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Impressive Bisantrene Phase 2 AML Clinical Results
|
|
SocialEddy
|
231 |
66K |
13 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
231
|
66K
|
13
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Release of Securities from Voluntary Escrow
|
|
SocialEddy
|
4 |
2.1K |
10 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
4
|
2.1K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Trading Halt
|
|
SocialEddy
|
62 |
21K |
3 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
62
|
21K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
AML Diagnosis - things to know
|
|
SocialEddy
|
10 |
4.0K |
40 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
10
|
4.0K
|
40
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Trading Halt
|
|
SocialEddy
|
62 |
21K |
8 |
05/11/23 |
05/11/23 |
ASX - By Stock
|
62
|
21K
|
8
|
|
ASX - By Stock
|
RAC |
Re:
ASH2023 - Sheba 2.0
|
|
SocialEddy
|
156 |
51K |
14 |
05/11/23 |
05/11/23 |
ASX - By Stock
|
156
|
51K
|
14
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Trading Halt
|
|
SocialEddy
|
62 |
21K |
5 |
04/11/23 |
04/11/23 |
ASX - By Stock
|
62
|
21K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
ASH2023 - Sheba 2.0
|
|
SocialEddy
|
156 |
51K |
10 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
156
|
51K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
ASH2023 - Sheba 2.0
|
|
SocialEddy
|
156 |
51K |
40 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
156
|
51K
|
40
|
|
ASX - By Stock
|
RAC |
Re:
ASH2023 - Sheba 2.0
|
|
SocialEddy
|
156 |
51K |
19 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
156
|
51K
|
19
|
|
ASX - By Stock
|
RAC |
Re:
ASH2023 - Sheba 2.0
|
|
SocialEddy
|
156 |
51K |
42 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
156
|
51K
|
42
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Notification regarding unquoted securities - RAC
|
|
SocialEddy
|
23 |
7.1K |
9 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
23
|
7.1K
|
9
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Notification regarding unquoted securities - RAC
|
|
SocialEddy
|
23 |
7.1K |
1 |
02/11/23 |
02/11/23 |
ASX - By Stock
|
23
|
7.1K
|
1
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
SocialEddy
|
11K |
3.8M |
3 |
01/11/23 |
01/11/23 |
General
|
11K
|
3.8M
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Letter to Shareholders, Notice of AGM & Proxy Form
|
|
SocialEddy
|
96 |
26K |
6 |
26/10/23 |
26/10/23 |
ASX - By Stock
|
96
|
26K
|
6
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Date of AGM and Closing Date for Director Nominations
|
|
SocialEddy
|
71 |
21K |
4 |
10/10/23 |
10/10/23 |
ASX - By Stock
|
71
|
21K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Date of AGM and Closing Date for Director Nominations
|
|
SocialEddy
|
71 |
21K |
0 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
71
|
21K
|
0
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Date of AGM and Closing Date for Director Nominations
|
|
SocialEddy
|
71 |
21K |
10 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
71
|
21K
|
10
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Date of AGM and Closing Date for Director Nominations
|
|
SocialEddy
|
71 |
21K |
4 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
71
|
21K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
|
|
SocialEddy
|
218 |
72K |
3 |
08/10/23 |
08/10/23 |
ASX - By Stock
|
218
|
72K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
|
|
SocialEddy
|
218 |
72K |
4 |
08/10/23 |
08/10/23 |
ASX - By Stock
|
218
|
72K
|
4
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
|
|
SocialEddy
|
218 |
72K |
1 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
218
|
72K
|
1
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
|
|
SocialEddy
|
218 |
72K |
3 |
07/10/23 |
07/10/23 |
ASX - By Stock
|
218
|
72K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
|
|
SocialEddy
|
218 |
72K |
18 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
218
|
72K
|
18
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
|
|
SocialEddy
|
218 |
72K |
25 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
218
|
72K
|
25
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
SocialEddy
|
11K |
3.8M |
5 |
04/10/23 |
04/10/23 |
General
|
11K
|
3.8M
|
5
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene cGMP API Manufacturing Completed at Laurus Labs
|
|
SocialEddy
|
74 |
27K |
75 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
74
|
27K
|
75
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene cGMP API Manufacturing Completed at Laurus Labs
|
|
SocialEddy
|
74 |
27K |
2 |
28/09/23 |
28/09/23 |
ASX - By Stock
|
74
|
27K
|
2
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene cGMP API Manufacturing Completed at Laurus Labs
|
|
SocialEddy
|
74 |
27K |
3 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
74
|
27K
|
3
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene cGMP API Manufacturing Completed at Laurus Labs
|
|
SocialEddy
|
74 |
27K |
5 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
74
|
27K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene cGMP API Manufacturing Completed at Laurus Labs
|
|
SocialEddy
|
74 |
27K |
64 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
74
|
27K
|
64
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
|
|
SocialEddy
|
218 |
72K |
5 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
218
|
72K
|
5
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
|
|
SocialEddy
|
218 |
72K |
16 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
218
|
72K
|
16
|
|
ASX - By Stock
|
RAC |
Re:
Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells
|
|
SocialEddy
|
218 |
72K |
20 |
21/09/23 |
21/09/23 |
ASX - By Stock
|
218
|
72K
|
20
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
SocialEddy
|
11K |
3.8M |
17 |
20/09/23 |
20/09/23 |
General
|
11K
|
3.8M
|
17
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
SocialEddy
|
11K |
3.8M |
10 |
20/09/23 |
20/09/23 |
General
|
11K
|
3.8M
|
10
|
|
ASX - By Stock
|
RAC Biotech |
Re:
RAC - Charts & Price Action
|
|
SocialEddy
|
21K |
7.3M |
1 |
18/09/23 |
18/09/23 |
ASX - By Stock
|
21K
|
7.3M
|
1
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
SocialEddy
|
11K |
3.8M |
12 |
14/09/23 |
14/09/23 |
General
|
11K
|
3.8M
|
12
|
|
ASX - By Stock
|
RAC |
Re:
ANN - Issuing of the official RACE Playlist
|
|
SocialEddy
|
32 |
9.7K |
23 |
13/09/23 |
13/09/23 |
ASX - By Stock
|
32
|
9.7K
|
23
|
|
ASX - By Stock
|
RAC Biotech |
Re:
Large BUY - ex insider/ ex CSO / new consultant - Dr Tillett
|
|
SocialEddy
|
143 |
51K |
2 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
143
|
51K
|
2
|
|
ASX - By Stock
|
RAC Biotech |
Re:
Large BUY - ex insider/ ex CSO / new consultant - Dr Tillett
|
|
SocialEddy
|
143 |
51K |
1 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
143
|
51K
|
1
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
SocialEddy
|
11K |
3.8M |
3 |
06/09/23 |
06/09/23 |
General
|
11K
|
3.8M
|
3
|
|
General
|
RAC |
Re:
General Comments / Chat
|
|
SocialEddy
|
11K |
3.8M |
8 |
06/09/23 |
06/09/23 |
General
|
11K
|
3.8M
|
8
|
|